Insulet (PODD) Down 8.2% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for Insulet (PODD). Shares have lost about 8.2% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Insulet due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Insulet Corporation before we dive into how investors and analysts have reacted as of late.Insulet Tops Q4 Earnings & Revenue EstimatesInsulet Corporation reported fourth-quarter 2025 adjusted earnings per share of $1.55, up 34.8% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 4.87%.GAAP earnings per share  came in at $1.44, up 3.6% from the year-ago quarter’s figure.Full-year 2025 earnings per share  of $4.97 increased 53.4% from the prior-year level. The figure topped the Zacks Consensus Estimate by 1.2%.PODD’s RevenuesRevenues totaled $783.8 million, which beat the Zacks Consensus Estimate by 2.15%. The top line jumped 31.2% year over year and 29% at constant exchange rate or CER, which exceeded the company’s high end of the guidance range of 25%-28%.Insulet reported full-year 2025 revenues of $2.71 billion, which increased 30.7% from the prior-year level. The figure surpassed the Zacks Consensus Estimate by 0.7%. PODD’s Q4 Segmental RevenuesInsulet’s total Omnipod revenues of $781.8 million reflected an increase of 33.5% year over year and 31.3% at CER.International Omnipod revenues of $214 million rose 50.7% (up 41.7% at CER). U.S. Omnipod revenues grew 28% year over year to $567.8 million.The Drug Delivery business’ revenues totaled $2 million, down 83.4% year over year.PODD’s Q4 Margin PerformanceThe gross profit in the reported quarter was $568.6 million, up 31.9% from the prior-year quarter’s figure. The gross margin of 72.5% expanded 32 basis points (bps) year over year.Selling, general & administrative expenses rose 27% year over year to $331.4 million.Research and development expenses jumped 50% year over year to $90.9 million.The operating profit in the quarter totaled $146.3 million, up 33.7% from the year-ago reported actuals. The operating margin of 18.7% expanded 36 bps year over year.Insulet’s Cash PositionInsulet exited the fourth quarter of 2025 with cash and cash equivalents of $716.1 million compared with $953.4 million at the end of 2024.  Cumulative net cash provided by operating activities at the end of the fourth quarter was $569.3 million compared with $430.2 million in the year-ago period.PODD’s 2026 OutlookInsulet provided guidance for full-year 2026. Total revenues are projected to grow 20%-22% at CER. Within this, Total Omnipod revenue growth is expected in the range of 21%-23%, while Drug Delivery revenues are expected to fall around 50% at CER.  The Zacks Consensus Estimate for the company’s 2025 revenues currently stands at $2.69 billion.For the first quarter, Insulet projects revenue growth of 25%-27%. Total Omnipod revenues are anticipated to rise 28%-30%. Drug Delivery revenues are expected to decline roughly 80%. The consensus mark for the company’s first-quarter revenues currently stands at $767.3 million.How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.VGM ScoresAt this time, Insulet has a strong Growth Score of A, though it is lagging a bit on the Momentum Score front with a B. Charting a somewhat similar path, the stock has a grade of C on the value side, putting it in the middle 20% for value investors.Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Insulet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerInsulet is part of the Zacks Medical - Products industry. Over the past month, Phibro Animal Health (PAHC), a stock from the same industry, has gained 1%. The company reported its results for the quarter ended December 2025 more than a month ago.Phibro reported revenues of $373.9 million in the last reported quarter, representing a year-over-year change of +20.9%. EPS of $0.87 for the same period compares with $0.54 a year ago.Phibro is expected to post earnings of $0.72 per share for the current quarter, representing a year-over-year change of +14.3%. Over the last 30 days, the Zacks Consensus Estimate has changed +1.1%.The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Phibro. Also, the stock has a VGM Score of D.#1 Semiconductor Stock to Buy (Not NVDA)The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Insulet Corporation (PODD): Free Stock Analysis Report Phibro Animal Health Corporation (PAHC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks